Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD.

Moreno S, Ibraghimov-Beskrovnaya O, Bukanov NO.

Cell Cycle. 2008 Jun 15;7(12):1856-64. Epub 2008 Jun 2.

PMID:
18583937
2.

Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O.

Nature. 2006 Dec 14;444(7121):949-52. Epub 2006 Nov 22.

PMID:
17122773
3.

CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.

Bukanov NO, Moreno SE, Natoli TA, Rogers KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L, Ibraghimov-Beskrovnaya O.

Cell Cycle. 2012 Nov 1;11(21):4040-6. doi: 10.4161/cc.22375. Epub 2012 Oct 3.

4.

Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy.

Ibraghimov-Beskrovnaya O.

Cell Cycle. 2007 Apr 1;6(7):776-9. Epub 2007 Apr 21. Review.

PMID:
17377490
5.

Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures.

Natoli TA, Gareski TC, Dackowski WR, Smith L, Bukanov NO, Russo RJ, Husson H, Matthews D, Piepenhagen P, Ibraghimov-Beskrovnaya O.

Am J Physiol Renal Physiol. 2008 Jan;294(1):F73-83. Epub 2007 Oct 10.

6.

Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.

Song H, Vita M, Sallam H, Tehranchi R, Nilsson C, Sidén A, Hassan Z.

Cancer Chemother Pharmacol. 2007 Nov;60(6):841-9. Epub 2007 Feb 22.

PMID:
17318617
7.

Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.

Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, Remuzzi G, Benigni A.

Arthritis Rheum. 2007 May;56(5):1629-37.

8.

The effect of paclitaxel on the progression of polycystic kidney disease in rodents.

Martinez JR, Cowley BD, Gattone VH 2nd, Nagao S, Yamaguchi T, Kaneta S, Takahashi H, Grantham JJ.

Am J Kidney Dis. 1997 Mar;29(3):435-44.

PMID:
9041221
9.

Advances in the pathogenesis and treatment of polycystic kidney disease.

Patel V, Chowdhury R, Igarashi P.

Curr Opin Nephrol Hypertens. 2009 Mar;18(2):99-106. doi: 10.1097/MNH.0b013e3283262ab0. Review.

10.

CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases.

Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ.

Kidney Int. 2008 Mar;73(6):684-90. Epub 2007 Dec 19. Review.

11.

Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.

Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H.

J Immunol. 2008 Feb 1;180(3):1954-61.

12.

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.

Eguchi T, Itadani H, Shimomura T, Kawanishi N, Hirai H, Kotani H.

Mol Cancer Ther. 2009 Jun;8(6):1460-72. doi: 10.1158/1535-7163.MCT-08-1159. Epub 2009 Jun 9.

13.
14.
15.

Drugging cell cycle kinases in cancer therapy.

Blagden S, de Bono J.

Curr Drug Targets. 2005 May;6(3):325-35. Review.

PMID:
15857291
16.

CDK inhibitors and immune responses.

Grant S.

Cell Cycle. 2009 Aug 15;8(16):2484. No abstract available.

PMID:
19684461
17.

Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models.

Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, Belenky A, Bukanov NO, Dackowski WR, Husson H, Russo RJ, Shayman JA, Ledbetter SR, Leonard JP, Ibraghimov-Beskrovnaya O.

Nat Med. 2010 Jul;16(7):788-92. doi: 10.1038/nm.2171. Epub 2010 Jun 20.

18.

Prime time for polycystic kidney disease: does one shot of roscovitine bring the cure?

Kuehn EW, Walz G.

Nephrol Dial Transplant. 2007 Aug;22(8):2133-5. Epub 2007 Apr 4. Review. No abstract available.

PMID:
17412700
19.

Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.

Gherardi D, D'Agati V, Chu TH, Barnett A, Gianella-Borradori A, Gelman IH, Nelson PJ.

J Am Soc Nephrol. 2004 May;15(5):1212-22.

20.

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.

Fischer PM, Gianella-Borradori A.

Expert Opin Investig Drugs. 2005 Apr;14(4):457-77. Review.

PMID:
15882121

Supplemental Content

Support Center